Radiation-Immune Interactions (Co-Investigator)
MB BCh, Ba(O) (Hons), MRCP (Onc), PhD
Clinical Career Development Fellow
Investigating activity of nucleic acid sensing pathways in the context of DNA damage and designing rational immuno-oncology combination treatment approaches
Dr Parkes trained at Queens University Belfast, completing her oncology fellowship training at the Northern Ireland Cancer Centre. During her training she was awarded a CRUK clinical fellowship, and completed her DPhil in the Kennedy lab, studying the immune consequences of DNA repair deficiency. During this time she discovered constitutive STING signaling in DNA repair deficient cancers. She now focuses on understanding how to exploit the consequences of STING signaling for clinical benefit.
Su Phyu, Postdoctoral Researcher
Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial
Sharma P. et al, (2019), Journal of Clinical Oncology, 37, 3484 - 3492
Alcohol intake, tobacco smoking, and esophageal adenocarcinoma survival: a molecular pathology epidemiology cohort study
McCain RS. et al, (2019), Cancer Causes & Control, 31, 1 - 11
Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma.
Turkington RC. et al, (2019), Gut
Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer
Humphries MP. et al, (2018), Journal of Oncology, 2018, 1 - 14
Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
Parkes EE. et al, (2016), Journal of the National Cancer Institute, 109, djw199 - djw199